SCHEMBL4312062

SCHEMBL4312062

CC(C)(C)OC(=O)n1nc(C=Cc2ccccc2Br)c2ccccc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K4 P45985 1/20 0.38
HSD11B1 P28845 1/20 0.37
LY96 Q9Y6Y9 1/20 0.36
CHRM2 P08172 1/20 0.35
CHRM4 P08173 1/20 0.35
CHRM1 P11229 1/20 0.35
CHRM3 P20309 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
PDGFRB P09619 1/20 0.34
FGFR1 P11362 1/20 0.34
FGFR3 P22607 1/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
LMNA P02545 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
ACHE P22303 1/20 0.32
NR1H2 P55055 1/20 0.32
ELANE P08246 3/20 0.32
F2 P00734 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4312058 1.00 MAP2K4 (0.38) MAP2K4HSD11B1LY96CHRM2CHRM4
SCHEMBL18098022 0.81 MAP2K4 (0.40) MAP2K4CHRM2CHRM4CHRM1CHRM3
SCHEMBL15902469 0.80 MAP2K4 (0.43) MAP2K4CHRM2CHRM4CHRM1CHRM3
SCHEMBL29443983 0.80 MAP2K4 (0.43) MAP2K4CHRM2CHRM4CHRM1CHRM3
SCHEMBL4315025 0.79 CHRM2 (0.39) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL4315020 0.79 CHRM2 (0.39) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL30786187 0.79 MAP2K4 (0.42) MAP2K4CHRM2CHRM4CHRM1CHRM3
SCHEMBL16791413 0.79 MAP2K4 (0.39) MAP2K4CHRM2CHRM4CHRM1CHRM3
SCHEMBL2674135 0.78 MAP2K4 (0.44) MAP2K4CHRM2CHRM4CHRM1CHRM3
SCHEMBL10126744 0.76 L3MBTL1 (0.46) L3MBTL1LMNAELANEF2PLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101111483-B IGF-1R inhibitors KYOWA HAKKO KIRIN CO.,LTD. (JP) 2011-12-14 CN disclosed
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 US disclosed
CN-101111483-A IGF-1R inhibitors KYOWA HAKKO KOGYO KK (JP) 2008-01-23 CN disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054508-A1 IGF-1R INHIBITOR IGF1R, IGFBP5, IGFBP1 MAP2K4 1642/4885HSD11B1 588/4885LY96 3237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.